Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

13.79
+0.13000.95%
Post-market: 13.790.00000.00%16:10 EDT
Volume:68.82K
Turnover:942.63K
Market Cap:2.41B
PE:136.60
High:13.79
Open:13.68
Low:13.59
Close:13.66
52wk High:17.74
52wk Low:9.77
Shares:174.43M
Float Shares:104.00M
Volume Ratio:0.77
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1010
EPS(LYR):2.60
ROE:1.46%
ROA:-1.24%
PB:1.91
PE(LYR):5.30

Loading ...

Orient Securities Keeps Their Buy Rating on HUTCHMED (China) (HCM)

TIPRANKS
·
Aug 19

CICC Adjusts HUTCHMED Outlook, Lifting Price Target to HK$26 on Strong Trial Results

Stock News
·
Aug 18

Citic Securities Sticks to Their Buy Rating for HUTCHMED (China) (HCM)

TIPRANKS
·
Aug 18

HUTCHMED Surges Nearly 4% on Positive Late-Stage Trial Results for Combination Therapy

Stock News
·
Aug 17

Hong Kong Stocks Rise on Monday on Tech Gains; Alibaba Rises 2%

MT Newswires Live
·
Aug 17

HUTCHMED Stock Surges on Positive Drug Trial Results for Lung Cancer Therapy Combination

Deep News
·
Aug 17

Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso

TIPRANKS
·
Aug 17

Hutchmed H1 FY26 Net Income Drops to $15.9 Million; Revenue Rises 0.22% to $278.3 Million

Reuters
·
Aug 14

HUTCHMED (China) (HCM) was downgraded to a Hold Rating at Daiwa

TIPRANKS
·
Aug 14

Press Release: Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dow Jones
·
Aug 08

AI-Powered Human Capital Management Market in China Surges 505.7% to 241 Million Yuan in 2025

Stock News
·
Aug 07

Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 06

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewswire
·
Aug 06

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewswire
·
Aug 05

UOB Kay Hian Remains a Buy on HUTCHMED (China) (HCM)

TIPRANKS
·
Aug 04

UBS Adjusts HUTCHMED Target Price to HK$29.5, Maintains Buy Rating

Stock News
·
Aug 03

Huatai Securities Sticks to Their Buy Rating for HUTCHMED (China) (HCM)

TIPRANKS
·
Aug 01

Hutchmed H1 Earnings Fall, Revenue Rises

MT Newswires Live
·
Jul 30

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

GlobeNewswire
·
Jul 30

Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating

TIPRANKS
·
Jul 27